外科理论与实践

外科理论与实践 >

2025 , Vol. 30 >Issue 06: 474 - 478

DOI: https://doi.org/10.16139/j.1007-9610.2025.06.03

专家论坛

胰腺癌新辅助治疗若干问题思考：从循证医学到精准医疗的范式转换

  • 康晓超 ,
  • 李轶楷 ,
  • 郭世伟 ,
  • 金钢
展开
  • 海军军医大学长海医院 肝胆胰脾外科， 上海 200433
金钢，E-mail: jingang@smmu.edu.cn

收稿日期: 2025-06-27

  网络出版日期: 2026-01-26

基金资助

上海市2023年度“科技创新行动计划”(23Y41900200)

收起

Reflections on key issues in neoadjuvant therapy for pancreatic cancer: a paradigm shift from evidence-based medicine to precision medicine

  • KANG Xiaochao ,
  • LI Yikai ,
  • GUO Shiwei ,
  • JIN Gang
Expand
  • Department of Hepatobiliary Pancreatic Spleen Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China

Received date: 2025-06-27

  Online published: 2026-01-26

Fold

摘要

胰腺癌新辅助治疗正经历从传统化疗向精准医疗的重大转变。本文从循证医学角度出发，结合最新临床研究进展，深入探讨胰腺癌新辅助治疗的前沿问题。重点关注免疫治疗联合策略、液体活检技术应用、人工智能（AI）辅助决策、个体化精准医疗等创新方向，并提出基于分子分型的个体化治疗策略、多组学整合的疗效预测模型以及标准化多学科协作诊疗体系等前瞻性观点。这些创新理念将推动胰腺癌新辅助治疗向更加精准、有效的方向发展。

关键词： 胰腺癌; 新辅助治疗; 精准医疗; 免疫治疗; 液体活检; 人工智能

本文引用格式

康晓超 , 李轶楷 , 郭世伟 , 金钢 . 胰腺癌新辅助治疗若干问题思考：从循证医学到精准医疗的范式转换[J]. 外科理论与实践, 2025 , 30(06) : 474 -478 . DOI: 10.16139/j.1007-9610.2025.06.03

Abstract

Neoadjuvant therapy for pancreatic cancer is undergoing a paradigm shift from conventional chemotherapy to precision medicine. This expert forum discussed cutting-edge issues in pancreatic cancer neoadjuvant therapy from an evidence-based perspective, incorporating the latest clinical research advances. We focused on innovative directions including immunotherapy combination strategies, liquid biopsy applications, artificial intelligence (AI)-assisted decision making, and individualized precision medicine. We proposed forward-looking concepts such as molecular subtyping-guided individualized treatment strategies, multi-omics integrated efficacy prediction models, and standardized multidisciplinary collaborative care systems. These innovative concepts will drive pancreatic cancer neoadjuvant therapy toward more precise and effective directions.

Key words： Pancreatic cancer; Neoadjuvant therapy; Precision medicine; Immunotherapy; Liquid biopsy; Artificial intelligence（AI）

参考文献

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[2] STOFFEL E M, BRAND R E, GOGGINS M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention[J]. Gastroenterology, 2023, 164(5):752-765.
[3] STROBEL O, NEOPTOLEMOS J, J?GER D, et al. Optimizing the outcomes of pancreatic cancer surgery[J]. Nat Rev Clin Oncol, 2019, 16(1):11-26.
[4] WU M Y, SHEN M, XU M D, et al. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma[J]. Gland Surg, 2020, 9(6):2125-2135.
[5] DAI G H, RU J, SI H Y, et al. A phase 1b/2 study of surufatinib plus camrelizumab,nab-paclitaxel,and S-1(NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma(mPDAC)[J]. J Clin Oncol, 2023, 41(16):4142.
[6] RENOUF D J, LOREE J M, KNOX J J, et al. The CCTG PA.7 phase Ⅱ trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma[J]. Nat Commun, 2022, 13(1):5020.
[7] PADRóN L J, MAURER D M, O’HARA M H, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial[J]. Nat Med, 2022, 28(6):1167-1177.
[8] KIRCHHAMMER N, TREFNY M P, AUF DER MAUR P, et al. Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment[J]. Sci Transl Med, 2022, 14(670):eabo3605.
[9] GALON J, BRUNI D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019, 18(3):197-218.
[10] KRUGER S, HEINEMANN V, ROSS C, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer[J]. Ann Oncol, 2018, 29(12):2348-2355.
[11] WATANABE F, SUZUKI K, AIZAWA H, et al. Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging[J]. Sci Rep, 2023, 13(1):4809.
[12] DU J, LU C, MAO L, et al. PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: a biomolecular exploratory, phase Ⅱ trial[J]. Cell Rep Med, 2023, 4(3):100972.
[13] GEMENETZIS G, GROOT V P, YU J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective cluster study[J]. Ann Surg, 2018, 268(3):408-420.
[14] NASIEF H, ZHENG C, SCHOTT D, et al. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer[J]. NPJ Precis Oncol, 2019, 3:25.
[15] FRAUNHOFFER N, HAMMEL P, CONROY T, et al. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma[J]. Ann Oncol, 2024, 35(9):780-791.
[16] CHAN-SENG-YUE M, KIM J C, WILSON G W, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution[J]. Nat Genet, 2020, 52(4):231-240.
[17] GOLAN T, HAMMEL P, RENI M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4):317-327.
[18] MAHADEVAN K K, MCANDREWS K M, LEBLEU V S, et al. KRASG12Dinhibition reprograms the microenvironment of early and advancedpancreatic cancer to promote FAS-mediated killing by CD8+ T cells[J]. Cancer Cell, 2023, 41:1606-620,e8.
[19] WASKO U N, JIANG J, DALTON T C, et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer[J]. Nature, 2024, 629(8013):927-936.
[20] SINGHAL A, LI B T, O’REILLY E M. Targeting KRAS in cancer[J]. Nat Med, 2024, 30(4):969-983.
[21] TEMPERO M A, MALAFA M P, AL-HAWARY M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457.
[22] KRISHNAN S, CHADHA A S, SUH Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation[J]. Int J Radiat Oncol Biol Phys, 2016, 94(4):755-765.
[23] ABI JAOUDE J, THUNSHELLE C P, KOUZY R, et al. Stereotactic versus conventional radiation therapy for patients with pancreatic cancer in the modern era[J]. Adv Radiat Oncol, 2021, 6(6):100763.
[24] HAMMEL P, HUGUET F, VAN LAETHEM J L, et al. Effect of chemoradiotherapy vs. chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial[J]. JAMA, 2016, 315(17):1844-1853.
[25] RAINER FIETKAU, MICHAEL GHADIMI, UWE A WITTEL, et al. Randomized phase Ⅲ trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial[J]. J Clin Oncol, 2022, 40(16):4008.
[26] TORGESON A, LLOYD S, BOOTHE D, et al. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer[J]. Cancer, 2017, 123(19):3816-3824.
[27] FAISAL F, TSAI H L, BLACKFORD A, et al. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer[J]. Am J Clin Oncol, 2016, 39(1):18-26.
[28] SAIF A, VERBUS E, ERICKSON B, et al. A randomized, phase Ⅱ, clinical trial of preoperative fractionated radiation therapy versus stereotactic body radiation therapy for resectable, borderline resectable, or locally advanced type a pancreatic adenocarcinoma[J]. Ann Surg Oncol, 2023, 30(2):688-690.
[29] BARCELLINI A, MOLINELLI S, VANOLI A, et al. Preoperative chemo-CIRT in Re/BRe pancreatic cancer: insights from a multicenter prospective phase Ⅱ clinical study (NCT03822936)[J]. Tumori, 2024, 110(6):470-474.
[30] SUGIURA T, TOYAMA H, FUKUTOMI A, et al. Randomized phase Ⅱ trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)[J]. J Hepatobiliary Pancreat Sci, 2023, 30(11):1249-1260.
Options
文章导航

/

〈 〉